<DOC>
	<DOC>NCT00398125</DOC>
	<brief_summary>To investigate safety, tolerability and anti-viral activity in Integrase-Na√Øve HIV-1 infected adults</brief_summary>
	<brief_title>Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion criteria: Documented HIV1 infection with screening viral load between 5000 and 300,000 copies/mL. Baseline CD4 cell count greater than 100. Females must be of nonchildbearing potential Not have received antiretroviral therapy in the 12 weeks prior to first dose. Exclusion criteria: Must not be infected with hepatitis B or C. Patients must not have any acute laboratory abnormality. Must not have any active CDC (Centers for Disease Control and Prevention)Category C disease (1993), except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>GSK364735</keyword>
	<keyword>HIV-1</keyword>
	<keyword>integrase inhibitor</keyword>
</DOC>